AC Immune First Half 2026 Financial and Corporate Update
AC Immune SA (NASDAQ: ACIU) reported a half-year update for June 30, 2026, highlighting Phase 2 VacSYn Part 1 full results for ACI-7104 in H2 2026, Phase 1/1b data for ACI-19764 in H2 2026, and Phase 1 PET results for ACI-19626. Cash was CHF 75.4m. Revenues were CHF 16.2m. A $12m Takeda milestone was triggered for ACI-24.
How this was made
The 30-second read
Why it matters
The key tradable elements are (1) funding runway into Q4 2027 supported by cash and milestone payments, and (2) catalyst scheduling for VacSYn (ACI-7104) and ABATE (ACI-24) with additional Phase 1/1b readouts in H2 2026.
Market read
Traders can use the update to recalibrate probability-weighted timelines for H2 2026 clinical catalysts and to assess balance-sheet runway risk.
What to watch
The update emphasizes timing (expected in H2 2026) more than presenting new quantitative efficacy results, which can reduce immediate trading impact versus a true data release.
Background
AC Immune provides a half-year 2026 corporate and financial update, emphasizing near-term clinical catalysts across wholly-owned programs and partner-funded milestones.
Ticker impact
AC Immune reports full Part 1 VacSYn Phase 2 results timing for H2 2026, plus $12M Takeda milestone and CHF75.4M cash into Q4 2027.
Moderate upside bias on trading days tied to H2 2026 catalyst expectations; limited immediate repricing unless investors treat the update as de-risking.
The article discloses funding runway (cash into Q4 2027) and milestone triggers ($12M Takeda, $4M grant, CHF10M Lilly upfront), but it does not provide new efficacy outcomes beyond stating Part 1 full results are expected in H2 2026.
Market effects
Highlights continued investor focus on neurodegeneration assets with near-term Phase 2/1b catalysts and partner-funded milestones.
Limited, as the disclosure is company-specific and not a broad European biotech funding or regulatory shift.
Low; partner names (Takeda, Lilly) are global, but the article does not announce new cross-company deals beyond existing collaborations.
Counterpoint
Cash runway and milestone receipts may be largely expected for a clinical-stage company, so the market may discount the update until actual H2 2026 efficacy/biomarker readouts are released.
Key entities
- companyAC Immune SA
Clinical-stage biopharmaceutical company updating pipeline progress, partner milestones, and cash runway.
- programACI-7104 (VacSYn)
Anti-alpha-syn active immunotherapy in Phase 2 Parkinson’s disease; Part 1 full results expected in H2 2026.
- programACI-24 (ABATE)
Anti-Abeta active immunotherapy; Cohort AD4 initiation triggered a $12M Takeda milestone.
- partnerTakeda
Partner that triggered a $12M milestone payment upon ABATE Cohort AD4 initiation.
- partnerLilly
Partnered Morphomer-Tau program amendment and milestone structure; CHF10M upfront disclosed.
